Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma Trading AD's EBIT per Share for the
three
months ended in Mar. 2026 was €0.31.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €1.10.
During the past 12 months, the average EBIT per Share Growth Rate of Sopharma Trading AD was 6.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 28.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 38.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 23.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sopharma Trading AD's EBIT per Share or its related term are showing as below:
FRA:6YH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -6.2 Med: 19.25 Max: 51.1
Current: 28.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Sopharma Trading AD was 51.10% per year. The lowest was -6.20% per year. And the median was 19.25% per year.
FRA:6YH's 3-Year EBIT Growth Rate is ranked better than 82.86% of 105
companies
in the Medical Distribution industry
Industry Median: 4.2
vs FRA:6YH: 28.30
Sopharma Trading AD (FRA:6YH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sopharma Trading AD EBIT per Share Related Terms
Sopharma Trading AD EBIT per Share Historical Data
* Premium members only.
The historical data trend for Sopharma Trading AD's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma Trading AD (FRA:6YH) has a EBIT per Share of €1.10 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sopharma Trading AD and its competitors. According to the industry distribution chart, Sopharma Trading AD ranks #18 out of 105 companies in the Medical Distribution industry, placing it in the top 17.1%.
Is Sopharma Trading AD's EBIT per Share too high?
Sopharma Trading AD's current EBIT per Share is €1.10. Based on the distribution chart, Sopharma Trading AD ranks #18 out of 105 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sopharma Trading AD has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's EBIT per Share compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma Trading AD ranks #18 out of 105 companies for EBIT per Share. This places Sopharma Trading AD in the top 17% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 4.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 4.20, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sopharma Trading AD and its competitors. For the Medical Distribution industry, the median EBIT per Share is 4.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma Trading AD's current EBIT per Share is €1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Sopharma Trading AD (FRA:6YH) has a current EBIT per Share of €1.10. The stock's GF Value™ is €7.38, compared to a current price of €2.74 — trading 62.9% below its estimated fair value. The current EBIT per Share is €1.10. Sopharma Trading AD's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sopharma Trading AD (FRA:6YH), the current EBIT per Share is €1.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma Trading AD (FRA:6YH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued.
The current stock price of €2.74 is trading 62.9% below its estimated GF Value™ of €7.38.
Key valuation signals for FRA:6YH:
EBIT per Share: €1.10
GF Value™: €7.38 vs. price of €2.74 (62.9% below fair value)
No single metric tells the full story. See the FRA:6YH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
82GF Score
Get the complete analysis for FRA:6YH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6YH has been successfully added to your 
